Bad Blood — Secrets and Lies in a Silicon Valley Startup

The Fraud That Fooled Everyone

Elizabeth Holmes was nineteen when she dropped out of Stanford to found Theranos. She was thirty-two when John Carreyrou’s Wall Street Journal investigation began unraveling the company’s claims. In between, she had convinced George Shultz, James Mattis, Henry Kissinger, and Rupert Murdoch to sit on her board, raised nearly $1 billion in funding, been named one of Time’s most influential people, and appeared on Forbes covers with a valuation of $9 billion.

None of it was real. The technology — a device that could run hundreds of diagnostic tests from a single finger-prick of blood — didn’t work. The tests Theranos ran for patients used conventional machines operated in violation of industry standards. Patients received false diagnoses. And Holmes, with her baritone voice and black turtleneck and Jobs mythology, maintained the fiction for years through a combination of charisma, legal intimidation, and the profound reluctance of powerful men to admit they had been fooled.

Carreyrou’s Method

Bad Blood works because Carreyrou is, first and foremost, an extraordinary journalist. He cultivated sources for years, protected whistleblowers who took enormous personal risks, and documented everything with Wall Street Journal precision. The book is a model of investigative method rendered as narrative without sacrificing any of its documentary credibility.

The courage of the sources — particularly Tyler Shultz, George Shultz’s grandson, who faced the full weight of Theranos’s legal team — gives the book its moral spine. These are people who knew what the exposure would cost them and provided information anyway.

The Enabling Culture

Carreyrou’s sharpest analysis is reserved not for Holmes but for the system that enabled her. Silicon Valley’s “fake it till you make it” culture — the tolerance for unrealized technology presented as fait accompli — is not criminal in software. Applied to blood diagnostic technology, it can kill people. The board members who failed to ask basic technological questions, the investors who prioritized vision over verification, the culture that mistook conviction for competence — all of it contributed to a fraud that endangered lives.

A Story That Continues

Holmes was convicted of wire fraud in 2022 and sentenced to eleven years. Balwani, Theranos’s president, received a longer sentence. The story Carreyrou broke changed what regulators and investors demand from health technology companies, and changed the cultural conversation about Silicon Valley’s self-mythology.

The Anatomy of a Deception

What makes Bad Blood more than a catalogue of misdeeds is Carreyrou’s meticulous reconstruction of how, mechanically, the fraud was sustained for so long, and the answer is a chilling study in organizational dysfunction. Theranos maintained its fiction through an architecture of secrecy and fear: extreme compartmentalization that kept employees from grasping the whole picture, aggressive non-disclosure agreements, a security apparatus that surveilled and intimidated staff, and the relentless legal threats — orchestrated by the famed attorney David Boies — that silenced doubters and terrified would-be whistleblowers. Demonstrations for investors and partners were staged with rigged or substituted equipment; failing tests were hidden; employees who raised concerns were isolated, demoted, or forced out. Carreyrou shows that the deception was not a single lie but a continuously maintained system, requiring the active complicity of some and the enforced silence of many more. The result is a portrait of how a culture of secrecy and intimidation can keep an enormous fraud running even as dozens of people inside the company know that something is deeply wrong.

The Reporter and the Whistleblowers

The book’s moral spine is the courage of the sources who risked everything to expose the truth, and Carreyrou’s account of his own investigation reads with genuine suspense. The whistleblowers — chief among them Tyler Shultz, grandson of board member and former Secretary of State George Shultz, and his colleague Erika Cheung — came forward knowing they would face the full weight of Theranos’s surveillance and legal machinery, and at real cost to their careers, finances, and family relationships. Carreyrou, then a Wall Street Journal reporter, cultivated these sources over many months, protected their identities against intense pressure, and pursued the story despite Theranos’s attempts to kill it through legal threats directed at both the sources and the newspaper. The narrative of the reporting itself — the cat-and-mouse with Boies’s lawyers, the frightened sources, the corroboration assembled piece by painstaking piece — becomes a gripping demonstration of investigative journalism’s value and of the personal bravery required to tell truth to power. It is a vindication of the press at a moment when its institutions are under strain.

The Culture That Made Her Possible

Carreyrou’s sharpest analysis is directed not at Elizabeth Holmes alone but at the Silicon Valley ethos that enabled her, and this is the book’s most broadly important argument. The “fake it till you make it” culture of startups — the tolerance for vaporware, the celebration of visionary founders, the reverence for the Steve Jobs mythology that Holmes consciously imitated down to the black turtleneck — is relatively harmless when applied to software that can be patched after launch. Applied to a medical device that delivers diagnoses on which patients make life-and-death decisions, it becomes lethal. Carreyrou documents how this culture, combined with the credulity of investors who prized vision over verification and a board of eminent men who failed to ask elementary technical questions, created the conditions in which a fraud of this scale could flourish. The book is thus a cautionary tale not merely about one charismatic deceiver but about a whole system of incentives that mistook conviction for competence and rewarded storytelling over substance — a warning that extends well beyond Theranos.

A Modern Classic of Business Journalism

Published in 2018, Bad Blood became an immediate bestseller and is now widely regarded as one of the finest works of business journalism of its generation, a benchmark against which subsequent accounts of corporate fraud are measured. Its reporting helped seal the legal fate of its subjects: Holmes was convicted of wire fraud in 2022 and sentenced to more than eleven years, and Theranos president Ramesh “Sunny” Balwani received a longer term. Beyond its narrative power, the book has had a lasting influence on how regulators, investors, and journalists scrutinize health-technology startups, and it has become a touchstone in conversations about the ethics of Silicon Valley. Carreyrou combines the documentary rigor of the dogged investigative reporter with the propulsive momentum of a thriller, producing a book that is at once authoritative and impossible to put down. As the definitive account of the Theranos fraud, and as a broader study of how ambition, charisma, and a permissive culture can curdle into mass deception, it is essential reading.

Our rating: 4.6/5 — The definitive account of the Theranos fraud, reported with extraordinary rigor and written with thriller momentum, essential for anyone trying to understand how Silicon Valley self-delusion becomes mass deception.

Reading Guides

• Best True Crime Books: 10 Essential Reads for the Genre
• Best Biographies of All Time: 24 Lives Worth Reading (2026)